Figure 5 | Experimental & Molecular Medicine

Figure 5

From: Combined blockade of HER2 and VEGF exerts greater growth inhibition of HER2-overexpressing gastric cancer xenografts than individual blockade

Figure 5

Viable and necrotic areas of tumors at the end of treatment. (a) Viable (green) and necrotic (black) areas, as differentiated by YO-PRO-1 staining and quantified by the ImageJ software program. The scale bar represents 1 mm. Viable (b) and necrotic tumor areas (c) after 28 days of treatment. (d) Viable and necrotic tumor areas are presented as a ratio (n=7; *P<0.05 versus isotype control; #P<0.05 versus vascular endothelial growth factor (VEGF)-Trap (VT); $P<0.05 versus trastuzumab (Tr)). IgG, immunoglobulin G.

Back to article page